leadf
logo-loader
viewCytoDyn Inc.

CytoDyn showcases its patient safety data from its Phase 2 coronavirus trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive it revealed patient safety data from a Phase 2 coronavirus trial of its drug leronlimab, which he says, showed significantly lower adverse events than a placebo.

Pourhassan explains why he believes the market didn't react as he expected it would, and spoke about the next steps regarding its trial.

Quick facts: CytoDyn Inc.

Price: 2.39 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.36 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn provide update on their path to approval for treatment of COVID-19

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to provide an update on how and when they expect to have approval for Leronlimab for Covid treatment.  Pourhassan also told Proactive about what the recent decision by the FDA to approve Remdesivir as a...

6 days, 18 hours ago

2 min read